Patents by Inventor Anthony Casarez
Anthony Casarez has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).
-
Publication number: 20230271954Abstract: Compounds are provided having structure (I): or a pharmaceutically acceptable salt, solvate, hydrate, isomer, or isotope thereof, wherein X, L, Y, R1, R2, R3 and Cy are as defined herein. Pharmaceutical compositions containing such compounds, as well as the compounds themselves, are also provided. Methods are provided wherein the compounds are inhibitors of one or both of diacylglycerol kinase alpha (DGK?) and diacylglycerol kinase zeta (DGK?) or are useful in the treatment of diseases, disorders and conditions related to DGK? and/or DGK? activity. More specifically, methods of treating a proliferative or a viral infection are provided by administering to a subject in need thereof, an effective amount of the pharmaceutical composition containing compounds of structure (I).Type: ApplicationFiled: August 4, 2022Publication date: August 31, 2023Inventors: Anthony Casarez, Terry Kellar
-
Patent number: 10919887Abstract: The invention provides new solid forms, salts and polymorphs of 1-(((Z)-(1-(2-aminothiazol-4-yl)-2-oxo-2-(((3S,4R)-2-oxo-4-((2-oxooxazolidin-3-yl)methyl)-1-sulfoazetidin-3-yl)amino)ethylidene)amino)oxy)cyclopropanecarboxylic acid (referred to herein as Compound X), pharmaceutical compositions containing them, and processes for their manufacture and use in therapy.Type: GrantFiled: September 20, 2016Date of Patent: February 16, 2021Assignee: Novartis AGInventors: Eric Aubin, Anthony Casarez, Andreas Fisch, Zaixing Li, Mika Lindvall, Heinz Ernst Moser, Michael Mutz, Folkert Reck, Bernd Ulrich Riebesehl, Marc Schoenhentz, Vijay Sethuraman, Robert Lowell Simmons
-
Publication number: 20200276169Abstract: This invention pertains generally to antibacterial compounds of Formula I, as further described herein, and pharmaceutically acceptable salts and formulations thereof. In certain aspects, the invention pertains to methods of using such compounds to treat infections such as those caused by Gram-negative bacteria.Type: ApplicationFiled: March 19, 2020Publication date: September 3, 2020Inventors: Virender Singh AULAKH, Anthony CASAREZ, Xiaodong LIN, Mika LINDVALL, Glenn MCENROE, Heinz Ernst MOSER, Folkert RECK, Meiliana TJANDRA, Robert Lowell SIMMONS, Aregahegn YIFRU, Qingming ZHU
-
Patent number: 10597396Abstract: This invention pertains generally to compounds of Formula (A), as further described herein, which act as beta-lactamase inhibitors, and salts, crystalline forms and formulations thereof. In certain aspects, the invention pertains to methods of using such compounds in combination with a beta-lactam antibiotic to treat infections caused by Gram-negative bacteria, including drug-resistant strains.Type: GrantFiled: September 28, 2017Date of Patent: March 24, 2020Assignee: Novartis AGInventors: Anthony Casarez, Markus Furegati, Guido Koch, Xiaodong Lin, Flavio Ossola, Folkert Reck, Robert Lowell Simmons, Qingming Zhu
-
Patent number: 10369138Abstract: This invention pertains generally to antibacterial compounds of Formula I, as further described herein, and pharmaceutically acceptable salts and formulations thereof. In certain aspects, the invention pertains to methods of using such compounds to treat infections such as those caused by Gram-negative bacteria.Type: GrantFiled: September 22, 2015Date of Patent: August 6, 2019Assignee: Novartis AGInventors: Virender Singh Aulakh, Anthony Casarez, Xiaodong Lin, Mika Lindvall, Glenn McEnroe, Heinz Ernst Moser, Folkert Reck, Meiliana Tjandra, Robert Lowell Simmons, Aregahegn Yifru, Qingming Zhu
-
Publication number: 20190231752Abstract: This invention pertains generally to antibacterial compounds of Formula I, as further described herein, and pharmaceutically acceptable salts and formulations thereof. In certain aspects, the invention pertains to methods of using such compounds to treat infections such as those caused by Gram-negative bacteria.Type: ApplicationFiled: April 10, 2019Publication date: August 1, 2019Inventors: Virender Singh AULAKH, Anthony CASAREZ, Xiaodong LIN, Mika LINDVALL, Glenn MCENROE, Heinz Ernst MOSER, Folkert RECK, Meiliana TJANDRA, Robert Lowell SIMMONS, Aregahegn YIFRU, Qingming ZHU
-
Publication number: 20190177324Abstract: This invention pertains generally to compounds of Formula (A), as further described herein, which act as beta-lactamase inhibitors, and salts, crystalline forms and formulations thereof. In certain aspects, the invention pertains to methods of using such compounds in combination with a beta-lactam antibiotic to treat infections caused by Gram-negative bacteria, including drug-resistant strains.Type: ApplicationFiled: September 28, 2017Publication date: June 13, 2019Applicant: Novartis AGInventors: Anthony CASAREZ, Markus FUREGATI, Guido KOCH, Xiaodong LIN, Flavio OSSOLA, Folkert RECK, Robert Lowell SIMMONS, Qingming ZHU
-
Publication number: 20180273522Abstract: The invention provides new solid forms, salts and polymorphs of 1-(((Z)-(1-(2-aminothiazol-4-yl)-2-oxo-2-(((3S,4R)-2-oxo-4-((2-oxooxazolidin-3-yl)methyl)-1-sulfoazetidin-3-yl)amino)ethylidene)amino)oxy)cyclopropanecarboxylic acid (referred to herein as Compound X), pharmaceutical compositions containing them, and processes for their manufacture and use in therapy.Type: ApplicationFiled: September 20, 2016Publication date: September 27, 2018Inventors: Eric AUBIN, Anthony CASAREZ, Andreas FISCH, Zaixing LI, Mika LINDVALL, Heinz Ernst MOSER, Michael MUTZ, Folkert RECK, Bernd Ulrich RIEBESEHL, Marc SCHOENHENTZ, Vijay SETHURAMAN, Robert Lowell SIMMONS
-
Patent number: 10065957Abstract: This invention pertains generally to compounds of Formula (A), as further described herein, which act as beta-lactamase inhibitors, and salts, crystalline forms and formulations thereof. In certain aspects, the invention pertains to methods of using such compounds in combination with a beta-lactam antibiotic to treat infections caused by Gram-negative bacteria, including drug-resistant strains.Type: GrantFiled: September 28, 2017Date of Patent: September 4, 2018Assignee: Novartis AGInventors: Anthony Casarez, Markus Furegati, Guido Koch, Xiaodong Lin, Flavio Ossola, Folkert Reck, Robert Lowell Simmons, Qingming Zhu
-
Publication number: 20180086762Abstract: This invention pertains generally to compounds of Formula (A), as further described herein, which act as beta-lactamase inhibitors, and salts, crystalline forms and formulations thereof. In certain aspects, the invention pertains to methods of using such compounds in combination with a beta-lactam antibiotic to treat infections caused by Gram-negative bacteria, including drug-resistant strains.Type: ApplicationFiled: September 28, 2017Publication date: March 29, 2018Inventors: Anthony CASAREZ, Markus FUREGATI, Guido KOCH, Xiaodong LIN, Flavio OSSOLA, Folkert RECK, Robert Lowell SIMMONS, Qingming ZHU
-
Publication number: 20160051523Abstract: This invention pertains generally to antibacterial compounds of Formula I, as further described herein, and pharmaceutically acceptable salts and formulations thereof. In certain aspects, the invention pertains to methods of using such compounds to treat infections such as those caused by Gram-negative bacteria.Type: ApplicationFiled: September 22, 2015Publication date: February 25, 2016Applicant: NOVARTIS AGInventors: Virender Singh AULAKH, Anthony CASAREZ, Xiaodong LIN, Mika LINDVALL, Glenn MCENROE, Heinz Ernst MOSER, Folkert RECK, Meiliana TJANDRA, Robert Lowell SIMMONS, Aregahegn YIFRU, Qingming ZHU
-
Patent number: 9174978Abstract: This invention pertains generally to antibacterial compounds of Formula I, as further described herein, and pharmaceutically acceptable salts and formulations thereof. In certain aspects, the invention pertains to methods of using such compounds to treat infections such as those caused by Gram-negative bacteria.Type: GrantFiled: March 23, 2015Date of Patent: November 3, 2015Assignee: Novartis AGInventors: Virender Singh Aulakh, Anthony Casarez, Xiaodong Lin, Mika Lindvall, Glenn McEnroe, Heinz Ernst Moser, Folkert Reck, Meiliana Tjandra, Robert Lowell Simmons, Aregahegn Yifru, Qingming Zhu
-
Publication number: 20150266867Abstract: This invention pertains generally to antibacterial compounds of Formula I, as further described herein, and pharmaceutically acceptable salts and formulations thereof. In certain aspects, the invention pertains to methods of using such compounds to treat infections such as those caused by Gram-negative bacteria.Type: ApplicationFiled: March 23, 2015Publication date: September 24, 2015Applicant: NOVARTIS AGInventors: Virender Singh AULAKH, Anthony CASAREZ, Xiaodong LIN, Mika LINDVALL, Glenn MCENROE, Heinz Ernst MOSER, Folkert RECK, Meiliana TJANDRA, Robert Lowell SIMMONS, Aregahegn YIFRU, Qingming ZHU
-
Patent number: 8674088Abstract: The invention is related to anti-viral phosphinate compounds, compositions containing such compounds, and therapeutic methods that include the administration of such compounds, as well as to processes and intermediates useful for preparing such compounds.Type: GrantFiled: October 27, 2010Date of Patent: March 18, 2014Assignee: Gilead Sciences, Inc.Inventors: Anthony Casarez, Kleem Chaudhary, Aesop Cho, Michael Clarke, Edward Doerffler, Maria Fardis, Choung U. Kim, Hyungjung Pyun, Xiaoning C. Sheng, Jianying Wang
-
Patent number: 8586744Abstract: The invention is related to a method of treating disorders associated with hepatitis C by administering to an individual a pharmaceutical composition which comprises a therapeutically effective amount of an anti-viral phosphinate compound.Type: GrantFiled: October 27, 2010Date of Patent: November 19, 2013Assignee: Gilead Sciences, Inc.Inventors: Anthony Casarez, Kleem Chaudhary, Aesop Cho, Michael Clarke, Edward Doerffler, Maria Fardis, Choung U. Kim, Hyungjung Pyun, Xiaoning C. Sheng, Jianying Wang
-
Patent number: 8476225Abstract: The invention is related to anti-viral compounds, compositions containing such compounds, and therapeutic methods that include the administration of such compounds, as well as to processes and intermediates useful for preparing such compounds.Type: GrantFiled: December 1, 2010Date of Patent: July 2, 2013Assignee: Gilead Sciences, Inc.Inventors: Anthony Casarez, Mingzhe Ji, Choung U. Kim, Xiaoning C. Sheng, Qiaoyin Wu
-
Publication number: 20110135604Abstract: The invention is related to anti-viral compounds, compositions containing such compounds, and therapeutic methods that include the administration of such compounds, as well as to processes and intermediates useful for preparing such compounds.Type: ApplicationFiled: December 1, 2010Publication date: June 9, 2011Applicant: Gilead Sciences, Inc.Inventors: Anthony Casarez, Mingzhe Ji, Choung U. Kim, Xiaoning C. Sheng, Qiaoyin Wu
-
Publication number: 20110081314Abstract: The invention is related to anti-viral phosphinate compounds, compositions containing such compounds, and therapeutic methods that include the administration of such compounds, as well as to processes and intermediates useful for preparing such compounds.Type: ApplicationFiled: October 27, 2010Publication date: April 7, 2011Applicant: Gilead Sciences, Inc.Inventors: Anthony Casarez, Kleem Chaudhary, Aesop Cho, Michael Clarke, Edward Doerffler, Maria Fardis, Choung U. Kim, Hyungjung Pyun, Xiaoning C. Sheng, Jianying Wang
-
Publication number: 20110082112Abstract: The invention is related to a method of treating disorders associated with hepatitis C by administering to an individual a pharmaceutical composition which comprises a therapeutically effective amount of an anti-viral phosphinate compound.Type: ApplicationFiled: October 27, 2010Publication date: April 7, 2011Applicant: Gilead Sciences, Inc.Inventors: Anthony Casarez, Kleem Chaudhary, Aesop Cho, Michael Clarke, Edward Doerffler, Maria Fardis, Choung U. Kim, Hyungjung Pyun, Xiaoning C. Sheng, Jianying Wang
-
Patent number: 7893264Abstract: The invention is related to anti-viral phosphinate compounds, compositions containing such compounds, and therapeutic methods that include the administration of such compounds, as well as to processes and intermediates useful for preparing such compounds.Type: GrantFiled: July 6, 2007Date of Patent: February 22, 2011Assignee: Gilead Sciences, Inc.Inventors: Anthony Casarez, Kleem Chaudhary, Aesop Cho, Michael Clarke, Edward Doerffler, Maria Fardis, Choung U. Kim, Hyungjung Pyun, Xiaoning C. Sheng, Jianying Wang